The Centers for Medicare & Medicaid Services today issued a proposed rule setting forth a bundled payment model for radiation oncology, which would be mandatory in certain areas of the country. Under the model, participants would receive a bundled payment for 90-day episodes of radiation therapy for 17 disease sites, including breast, lung, prostate, kidney and colorectal cancer. This bundled payment would be made instead of regular Medicare fee-for-service payments; providers would keep any savings if spending is less than the bundled payment, subject to quality and patient experience measures, but also would be responsible for any spending above the payment amount. In addition, the model is designed to be site-neutral — that is, the bundled payment amount is designed to be calculated similarly regardless of whether the provider is a physician, hospital outpatient department or non-hospital setting. CMS proposes to run the model for five years, beginning either Jan. 1 or April 1, 2020. The proposed rule is expected to be published in the Federal Register soon, and CMS will accept comment for 60 days after publication. 

Related News Articles

Headline
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
Ashley Thompson, AHA senior vice president of public policy analysis and development, participated in a panel discussion during Modern Healthcare's Leadership…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…